20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
20 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 8 | 6 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 5 | 7 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 2 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $294.95, a high estimate of $364.00, and a low estimate of $215.00. This current average represents a 4.71% decrease from the previous average price target of $309.54.
Understanding Analyst Ratings: A Comprehensive Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive Biogen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Chris Schott | JP Morgan | Lowers | Neutral | $240.00 | $270.00 |
| Carter Gould | Barclays | Lowers | Equal-Weight | $215.00 | $230.00 |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $340.00 | - |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $364.00 | - |
| Salim Syed | Mizuho | Lowers | Buy | $277.00 | $355.00 |
| Eric Schmidt | Cantor Fitzgerald | Maintains | Overweight | $311.00 | - |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $305.00 | $310.00 |
| Colin Bristow | UBS | Lowers | Neutral | $250.00 | $276.00 |
| Brian Skorney | Baird | Lowers | Outperform | $316.00 | $333.00 |
| Christopher Raymond | Piper Sandler | Lowers | Overweight | $325.00 | $350.00 |
| Evan Seigerman | BMO Capital | Lowers | Outperform | $285.00 | $295.00 |
| Jay Olson | Oppenheimer | Lowers | Outperform | $290.00 | $295.00 |
| Brian Abrahams | RBC Capital | Lowers | Outperform | $364.00 | $379.00 |
| Mohit Bansal | Wells Fargo | Lowers | Equal-Weight | $240.00 | $315.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $325.00 | - |
| Ami Fadia | Needham | Lowers | Buy | $300.00 | $305.00 |
| Ami Fadia | Needham | Maintains | Buy | $305.00 | - |
| Jay Olson | Oppenheimer | Maintains | Outperform | $295.00 | - |
| Colin Bristow | UBS | Lowers | Neutral | $276.00 | $311.00 |
| Colin Bristow | UBS | Announces | Neutral | $276.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biogen compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Biogen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Biogen's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Biogen analyst ratings.
Unveiling the Story Behind Biogen
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Biogen: Financial Performance Dissected
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Biogen's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -6.2%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biogen's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 10.46%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Biogen's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.71%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Biogen's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.91%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.5.
What Are Analyst Ratings?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!